Leading the way to safer medication
 Crosscheck  Recommender

Antithymocyte immunoglobulin

Also known as: ATG Anti-thymocyte globulin

Brand names: ATGAM

Therapeutic Indications

Antithymocyte immunoglobulin is indicated for:

Prophylaxis of graft rejection

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1.0-2.5 mg/kg once daily

Steroid resistant graft rejection

Irrespective of gender only Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1.5 mg/kg once daily

Contraindications

Active ingredient Antithymocyte immunoglobulin is contraindicated in the following cases:

Infections

No gender/age discrimination

Active acute or chronic infections, which would contraindicate any additional immunosuppression.

Antithymocyte immunoglobulin is routinely used in combination with other immunosuppressive agents. Infections (bacterial, fungal, viral and protozoal), reactivation of infection (particularly CMV) and sepsis have been reported after antithymocyte immunoglobulin administration in combination with multiple immunosuppressive agents. In rare cases, these infections have been fatal.